Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors.

Wang LX, Plautz GE.

Breast Cancer Res Treat. 2012 Jul;134(1):61-70. doi: 10.1007/s10549-011-1912-5. Epub 2011 Dec 16.

2.

Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure.

Wang LX, Plautz GE.

J Immunol. 2010 May 15;184(10):5612-8. doi: 10.4049/jimmunol.0903549. Epub 2010 Apr 9.

4.

Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

Kuriyama H, Watanabe S, Kjaergaard J, Tamai H, Zheng R, Weinberg AD, Hu HM, Cohen PA, Plautz GE, Shu S.

Cell Immunol. 2006 Sep;243(1):30-40. Epub 2007 Jan 17.

PMID:
17207783
5.
6.

Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE.

J Neurosurg. 2005 Jul;103(1):156-64.

PMID:
16121986
7.

Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells.

Wang LX, Huang WX, Graor H, Cohen PA, Kim JA, Shu S, Plautz GE.

J Transl Med. 2004 Nov 26;2(1):41.

8.
9.

Considerations on clinical use of T cell immunotherapy for cancer.

Plautz GE, Cohen PA, Shu S.

Arch Immunol Ther Exp (Warsz). 2003;51(4):245-57. Review.

PMID:
12956434
10.

Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.

Peng L, Kjaergäard J, Plautz GE, Awad M, Drazba JA, Shu S, Cohen PA.

J Immunol. 2002 Nov 1;169(9):4811-21.

12.

Adoptive immunotherapy of CNS malignancies.

Plautz GE, Shu S.

Cancer Chemother Biol Response Modif. 2001;19:327-38. Review.

PMID:
11686021
13.

T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.

Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S.

Crit Rev Immunol. 2001;21(1-3):215-48. Review.

PMID:
11642606
14.

Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.

Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.

Otolaryngol Head Neck Surg. 2001 Apr;124(4):436-41.

PMID:
11283503
15.
16.

Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.

Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA.

J Immunol. 2000 Nov 15;165(10):5738-49.

18.

Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, Dasko D, Kim JA, Plautz GE, Leff BE, Smith V, Sandstrom-Wakeling K, Shu S.

Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1225-31.

PMID:
11031409
19.

T cell adoptive immunotherapy of newly diagnosed gliomas.

Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S.

Clin Cancer Res. 2000 Jun;6(6):2209-18.

20.

CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S.

Crit Rev Immunol. 2000;20(1):17-56. Review.

PMID:
10770269
22.

Allogeneic class I major histocompatibility complex gene transfer in murine neuroblastoma in vivo.

Ishida H, Kaneda Y, Yamane S, Sawada T, Plautz GE, Matsumura T.

Anticancer Res. 1999 Nov-Dec;19(6B):5367-73.

PMID:
10697563
23.
24.

T-cell adoptive immunotherapy of metastatic renal cell carcinoma.

Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE, Yetman RJ, Pienkny A, Sandstrom K, Shu S.

Urology. 1999 Oct;54(4):617-23; discussion 623-4.

PMID:
10510917
25.

Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.

Mukai S, Kagamu H, Shu S, Plautz GE.

Cell Immunol. 1999 Mar 15;192(2):122-32.

PMID:
10087180
26.

Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.

Liu J, Finke J, Krauss JC, Shu S, Plautz GE.

Cancer Immunol Immunother. 1998 Jul;46(5):268-76.

PMID:
9690455
27.

Systemic T cell adoptive immunotherapy of malignant gliomas.

Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciano M, Kangisser DB, Shu S.

J Neurosurg. 1998 Jul;89(1):42-51.

PMID:
9647171
28.

Tumor immunology.

Shu S, Plautz GE, Krauss JC, Chang AE.

JAMA. 1997 Dec 10;278(22):1972-81. Review.

PMID:
9396660
29.

Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

Plautz GE, Touhalisky JE, Shu S.

Cell Immunol. 1997 Jun 15;178(2):101-7.

PMID:
9225000
30.
31.

Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.

Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S.

Cancer Res. 1996 Oct 1;56(19):4338-42.

32.

Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

Plautz GE, Inoue M, Shu S.

Cell Immunol. 1996 Aug 1;171(2):277-84.

PMID:
8806798
33.

Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene.

Wahl WL, Strome SE, Nabel GJ, Plautz GE, Cameron MJ, San H, Fox BA, Shu S, Chang AE.

J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):1-11.

PMID:
7728301
34.

Direct gene transfer for the understanding and treatment of human disease.

Plautz GE, Nabel EG, Fox B, Yang ZY, Jaffe M, Gordon D, Chang A, Nabel GJ.

Ann N Y Acad Sci. 1994 May 31;716:144-53. Review.

35.

Recombinant growth factor gene expression in vascular cells in vivo.

Nabel EG, Plautz GE, Nabel GJ.

Ann N Y Acad Sci. 1994 Apr 18;714:247-52. Review.

36.

Gene transfer and vascular disease.

Nabel EG, Pompili VJ, Plautz GE, Nabel GJ.

Cardiovasc Res. 1994 Apr;28(4):445-55. Review.

PMID:
8181030
37.

Immunotherapy for cancer by direct gene transfer into tumors.

Nabel GJ, Chang AE, Nabel EG, Plautz GE, Ensminger W, Fox BA, Felgner P, Shu S, Cho K.

Hum Gene Ther. 1994 Jan;5(1):57-77. No abstract available.

PMID:
8155772
38.

Molecular genetic interventions for cancer.

Nabel GJ, Nabel EG, Yang Z, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE.

Cold Spring Harb Symp Quant Biol. 1994;59:699-707. No abstract available.

PMID:
7587133
39.

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11.

40.

Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy.

San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L, Felgner JH, Wheeler CJ, Felgner PL, Gao X, et al.

Hum Gene Ther. 1993 Dec;4(6):781-8.

41.

Immunotherapy of malignancy by in vivo gene transfer into tumors.

Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4645-9.

42.

Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization.

Nabel EG, Gordon D, Yang ZY, Xu L, San H, Plautz GE, Wu BY, Gao X, Huang L, Nabel GJ.

Hum Gene Ther. 1992 Dec;3(6):649-56.

43.

Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice.

Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, Huang L, Nabel EG, Nabel GJ.

Hum Gene Ther. 1992 Jun;3(3):267-75.

Supplemental Content

Loading ...
Support Center